Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
23.32
-0.25 (-1.06%)
Aug 14, 2025, 11:26 AM - Market open

Inhibrx Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Net Income
-134.261,688-241.36-115.33
Depreciation & Amortization
2.792.291.191.23
Other Amortization
-0.082.074.9-
Loss (Gain) From Sale of Assets
0.010.0100.02
Loss (Gain) on Equity Investments
--1.63-
Stock-Based Compensation
9.8158.5224.8517.79
Other Operating Activities
1.83-1,9970.131.62
Change in Accounts Receivable
1.070.38-0.540.13
Change in Accounts Payable
-4.317.92.11-0.38
Change in Unearned Revenue
---0.17-1.1
Change in Other Net Operating Assets
6.0133.7713.945.21
Operating Cash Flow
-117.11-194.41-193.31-90.81
Capital Expenditures
-0.28-2.6-4.59-0.69
Investing Cash Flow
-0.28-2.6-4.59-0.69
Issuance of Common Stock
-71.68202.32-
Other Financing Activities
41.31--0.3691.5
Financing Cash Flow
102.5571.68201.9691.5
Net Cash Flow
-14.85-125.334.06-
Free Cash Flow
-117.4-197.01-197.9-91.5
Free Cash Flow Margin
-8385.50%-98503.00%-10994.56%-6957.95%
Free Cash Flow Per Share
-7.59-13.15-16.80-
Cash Interest Paid
4.6111.5126.72-
Cash Income Tax Paid
0000
Levered Free Cash Flow
-48.4-118.26-106.38-
Unlevered Free Cash Flow
-44.67-111.89-91.38-
Change in Working Capital
2.7852.0515.353.86
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q